CYTOMED THERAPEUTICS LTD (GDTC) Forecast, Price Target & Analyst Ratings
NASDAQ:GDTC • SGXZ17669631
1.02 USD
-0.03 (-2.86%)
Last: Mar 4, 2026, 12:38 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CYTOMED THERAPEUTICS LTD (GDTC).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateApr 28, 2026
PeriodQ3 / 2025
EPS Estimate-SGD0.04
Revenue Estimate132.6K
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $1.02 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
GDTC was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about GDTC.
In the previous month the buy percentage consensus was at a similar level.
GDTC was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-10-10 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2024-06-11 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-12-04 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-07-21 | Benchmark | Initiate | Speculative Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 28, 2026
PeriodQ3 / 2025
EPS Estimate-SGD0.04
Revenue Estimate132.6K
Revenue Q2Q0.00%
EPS Q2Q0.00%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
GDTC is expected to report earnings on 4/28/2026. The consensus EPS estimate for the next earnings is -0.04 USD and the consensus revenue estimate is 132.60K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|
| Revenue YoY % growth | 69.5K | 530.4K 663.17% | |||
| EBITDA YoY % growth | -2.56M -84.17% | -3.56M -39.08% | -2.2M 38.21% | N/A | |
| EBIT YoY % growth | -2.95M -71.51% | -3.942M -33.61% | -2.535M 35.68% | -1.883M 25.73% | |
| Operating Margin | N/A | N/A | -3,648.06% | -355.00% | |
| EPS YoY % growth | N/A | N/A | N/A 42.31% | -0.17 -13.33% |
All data in SGD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.04 | -0.04 |
| Revenue Q2Q % growth | 132.6K | 132.6K 90.79% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -471.24K | -471.24K 47.02% |
All data in SGD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CYTOMED THERAPEUTICS LTD / GDTC Forecast FAQ
Can you provide the upcoming earnings date for CYTOMED THERAPEUTICS LTD?
CYTOMED THERAPEUTICS LTD (GDTC) will report earnings on 2026-04-28.
What are the consensus estimates for GDTC stock next earnings?
The consensus EPS estimate for the next earnings of CYTOMED THERAPEUTICS LTD (GDTC) is -0.04 USD and the consensus revenue estimate is 132.60K USD.
Can you provide the analyst count for CYTOMED THERAPEUTICS LTD stock?
The number of analysts covering CYTOMED THERAPEUTICS LTD (GDTC) is 7.